Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06688799 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

StatusRecruiting
PhasePhase 1/2
Started2024-11-23
View on ClinicalTrials.gov ↗

Amendment history

2026-03-06
minor
Study Status v2
Primary completion date2025-09→2026-03
2024-12-08
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Completion date2025-12→2026-12
Start dateestimated 2024-11→confirmed 2024-11-23
Study sitesdetails revised at 1 of 1 site
2024-11-12
minor
Original filing
The goal of this study is to evaluate the safety and effi cacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases.
Trial Details
NCT Number NCT06688799
Lead Sponsor Beijing GoBroad Hospital
Conditions Autoimmune Diseases
Enrollment 18 participants
Start Date 2024-11-23
Primary Completion 2026-03 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-10